The above analyses suggest that the detection of the SHOX2 methylation may become a specific and promising noninvasive biomarker for the diagnosis of patients with lung cancer using bronchial aspirates, especially in SCC and SCLC. This evidence concerns the gene SHOX2 and lung cancer.